Glenmark Pharmaceuticals gets FDA approval for generic MetroGel
The drug is used to treat bacterial vaginosis and is a generic version of Bausch Health US LLC’s MetroGel-Vaginal.
The US Food & Drug Administration (FDA) granted final approval to Glenmark Pharmaceuticals (Glenmark) on Friday for its metronidazole topical gel as a generic version of Bausch Health US LLC’s MetroGel-Vaginal.1
According to IQVIA sales data for the 12-month period ending in November 2021, MetroGel-Vaginal reported annual sales of approximately $60.4 million.
The global pharmaceutical company’s key therapeutic areas of focus include respiratory, dermatology, and oncology.
Glenmark’s new product adds to the firm’s growing portfolio of 173 products authorized for US distribution, with an additional 46 abbreviated new drug applications pending FDA approval.
Reference
- Glenmark Pharmaceuticals Receives ANDA Approval for Metronidazole Vaginal Gel, 0.75%. Accessed January 31, 2022. https://www.glenmarkpharma.com/sites/default/files/Glenmark-receives-ANDA-approval-for-Metronidazole-Vaginal-Gel-0-75%25_0.pdf
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
Understanding VTE and bleeding risks in gynecologic noncancer surgery
April 15th 2024Delve into the nuanced risks of venous thromboembolism and major bleeding post-gynecologic noncancer surgery, exploring procedure-specific variations and the implications for thromboprophylaxis strategies.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More
